Transgene Biotek Financial Statements
Transgene Biotek Quarterly Results
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
| Growth matrix (%) | ||||
| Revenue growth | (97) | (58) | 54.70 | (42) |
| Op profit growth | (59) | (18) | 126 | (30) |
| EBIT growth | 129 | (76) | (9.50) | 14.40 |
| Net profit growth | 70.30 | (68) | (7.80) | 12.60 |
| Profitability ratios (%) | ||||
| OPM | (24,156) | (1,781) | (912) | (623) |
| EBIT margin | (295,958) | (3,911) | (6,919) | (11,824) |
| Net profit margin | (306,602) | (5,445) | (7,072) | (11,864) |
| RoCE | (20) | (6.70) | (15) | (11) |
| RoNW | (6.40) | (2.90) | (4.30) | (2.90) |
| RoA | (5.20) | (2.30) | (3.80) | (2.70) |
| Per share ratios () | ||||
| EPS | -- | -- | -- | -- |
| Dividend per share | -- | -- | -- | -- |
| Cash EPS | (2.80) | (2.20) | (4.90) | (5.50) |
| Book value per share | 4.31 | 6.92 | 7.77 | 23 |
| Valuation ratios | ||||
| P/E | -- | -- | -- | -- |
| P/CEPS | (1.10) | (1) | (0.40) | (0.30) |
| P/B | 0.70 | 0.30 | 0.23 | 0.08 |
| EV/EBIDTA | (48) | 4.86 | (16) | (30) |
| Payout (%) | ||||
| Dividend payout | -- | -- | -- | -- |
| Tax payout | -- | 13.90 | -- | -- |
| Liquidity ratios | ||||
| Debtor days | 1,021 | 30.90 | 1,072 | 18,136 |
| Inventory days | 4,083 | 170 | 91 | 141 |
| Creditor days | (196) | (89) | (89) | (2,285) |
| Leverage ratios | ||||
| Interest coverage | 27.80 | 4.50 | 45.20 | 294 |
| Net debt / equity | 0.31 | 0.19 | 0.27 | 0.09 |
| Net debt / op. profit | (12) | (4.60) | (6.20) | (13) |
| Cost breakup () | ||||
| Material costs | (414) | (41) | -- | (0.40) |
| Employee costs | (8,098) | (277) | (197) | (375) |
| Other costs | (15,744) | (1,562) | (815) | (347) |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
| Revenue | -- | 0.12 | 0.28 | 0.18 |
| yoy growth (%) | (97) | (58) | 54.70 | (42) |
| Raw materials | -- | -- | -- | -- |
| As % of sales | 414 | 41.20 | -- | 0.41 |
| Employee costs | (0.30) | (0.30) | (0.60) | (0.70) |
| As % of sales | 8,098 | 277 | 197 | 375 |
| Other costs | (0.60) | (1.80) | (2.30) | (0.60) |
| As % of sales | 15,744 | 1,562 | 815 | 347 |
| Operating profit | (0.90) | (2.10) | (2.60) | (1.10) |
| OPM | (24,156) | (1,781) | (912) | (623) |
| Depreciation | (9.90) | (9.90) | (18) | (21) |
| Interest expense | (0.40) | (1) | (0.40) | (0.10) |
| Other income | 0.18 | 7.37 | 0.66 | 0.17 |
| Profit before tax | (11) | (5.70) | (20) | (22) |
| Taxes | -- | (0.80) | -- | -- |
| Tax rate | -- | 13.90 | -- | -- |
| Minorities and other | -- | -- | -- | -- |
| Adj. profit | (11) | (6.40) | (20) | (22) |
| Exceptional items | -- | -- | -- | -- |
| Net profit | (11) | (6.40) | (20) | (22) |
| yoy growth (%) | 70.30 | (68) | (7.80) | 12.60 |
| NPM | (306,602) | (5,445) | (7,072) | (11,864) |
- Switch to
-
Tabular DataGraph
| Y/e 31 Mar ( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
| Profit before tax | (11) | (5.70) | (20) | (22) |
| Depreciation | (9.90) | (9.90) | (18) | (21) |
| Tax paid | -- | (0.80) | -- | -- |
| Working capital | (33) | (4.30) | (2.40) | (0.70) |
| Other operating items | -- | -- | -- | -- |
| Operating cashflow | (54) | (21) | (40) | (43) |
| Capital expenditure | (7.40) | (8.60) | (101) | -- |
| Free cash flow | (61) | (29) | (141) | (43) |
| Equity raised | 178 | 238 | 269 | 250 |
| Investments | -- | -- | -- | -- |
| Debt financing/disposal | 2.97 | 17.80 | 26.60 | 16.50 |
| Dividends paid | -- | -- | -- | -- |
| Other items | -- | -- | -- | -- |
| Net in cash | 119 | 227 | 155 | 224 |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar ( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
| Equity capital | 75.80 | 75.80 | 75.80 | 75.80 |
| Preference capital | -- | -- | -- | -- |
| Reserves | (43) | (32) | (23) | (17) |
| Net worth | 32.70 | 43.60 | 52.40 | 58.90 |
| Minority interest | ||||
| Debt | 10.30 | 9.14 | 9.84 | 16 |
| Deferred tax liabilities (net) | -- | -- | -- | -- |
| Total liabilities | 43 | 52.80 | 62.30 | 74.90 |
| Fixed assets | 33.10 | 43 | 52.80 | 63.20 |
| Intangible assets | ||||
| Investments | -- | -- | -- | -- |
| Deferred tax asset (net) | -- | -- | -- | -- |
| Net working capital | 9.90 | 9.70 | 9.34 | 11.60 |
| Inventories | 0.04 | 0.03 | 0.04 | 0.07 |
| Inventory Days | 4,083 | -- | 123 | 91 |
| Sundry debtors | 0.01 | 0.01 | 0.01 | 0.01 |
| Debtor days | 1,021 | -- | 30.90 | 13 |
| Other current assets | 134 | 133 | 134 | 135 |
| Sundry creditors | (0.40) | (0.30) | (0.60) | (0.50) |
| Creditor days | 38,793 | -- | 1,698 | 702 |
| Other current liabilities | (123) | (123) | (124) | (123) |
| Cash | 0.04 | 0.10 | 0.10 | 0.05 |
| Total assets | 43 | 52.80 | 62.30 | 74.90 |
- Switch to
-
ConsolidatedStandalone
| Particulars ( Rupees In Crores.) | Mar-2021 | Dec-2020 | Sep-2020 | Jun-2020 | Mar-2020 |
|---|---|---|---|---|---|
| Gross Sales | 0.01 | 0.16 | -- | -- | -- |
| Excise Duty | -- | -- | -- | -- | -- |
| Net Sales | 0.01 | 0.16 | -- | -- | -- |
| Other Operating Income | -- | -- | -- | -- | -- |
| Other Income | 0.13 | 0.05 | 0.04 | 0.04 | 0.04 |
| Total Income | 0.14 | 0.21 | 0.04 | 0.04 | 0.04 |
| Total Expenditure ** | 0.20 | 0.18 | 0.18 | 0.14 | 0.28 |
| PBIDT | (0.10) | 0.03 | (0.10) | (0.10) | (0.20) |
| Interest | 0.07 | 0.07 | 0.07 | 0.07 | 0.08 |
| PBDT | (0.10) | -- | (0.20) | (0.20) | (0.30) |
| Depreciation | 2.48 | 2.48 | 2.47 | 2.47 | 2.47 |
| Minority Interest Before NP | -- | -- | -- | -- | -- |
| Tax | -- | -- | -- | -- | -- |
| Deferred Tax | -- | -- | -- | -- | -- |
| Reported Profit After Tax | (2.60) | (2.50) | (2.70) | (2.60) | (2.80) |
| Minority Interest After NP | -- | -- | -- | -- | -- |
| Net Profit after Minority Interest | (2.60) | (2.50) | (2.70) | (2.60) | (2.80) |
| Extra-ordinary Items | -- | -- | -- | -- | -- |
| Adjusted Profit After Extra-ordinary item | (2.60) | (2.50) | (2.70) | (2.60) | (2.80) |
| EPS (Unit Curr.) | (0.30) | (0.30) | (0.40) | (0.40) | (0.40) |
| Book Value (Unit Curr.) | -- | -- | -- | -- | -- |
| Dividend (%) | -- | -- | -- | -- | -- |
| Equity | 75.80 | 75.80 | 75.80 | 75.80 | 75.80 |
| Public Shareholding (Number) | -- | -- | -- | -- | -- |
| Public Shareholding (%) | -- | -- | -- | -- | -- |
| Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | -- |
| Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | -- |
| Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | -- |
| Non Encumbered - No. of Shares | -- | -- | -- | -- | -- |
| Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | -- |
| Non Encumbered - % in Total Equity | -- | -- | -- | -- | -- |
| PBIDTM(%) | (600) | 18.80 | -- | -- | -- |
| PBDTM(%) | (1,300) | (25) | -- | -- | -- |
| PATM(%) | (26,100) | (1,575) | -- | -- | -- |
QuickLinks for Transgene Biotek Ltd.
